Szabolcs I, Késmárki N, Bor K, Czirják S, Dohán O, Slovik F, Góth M, Kovács L, Ferencz A, Rimanóczy E, Szilágyi G
1st Department of Medicine, Haynal Imre University of Health Sciences, Budapest, Hungary.
Exp Clin Endocrinol Diabetes. 1997;105(4):234-6. doi: 10.1055/s-0029-1211758.
The case history of a 54-year-old male suffering from pituitary macroadenoma with suprasellar extension is reported. A TRH-test with 200 micrograms i.v. was followed by severe headache and vomiting after 60', and by development of ophthalmoplegia on the following day. Hyperdens patches on the CT scan showed haemorrhage into the tumor. A chromophobic adenoma with macroscopic and histological signs of haemorrhage was removed via the transsphenoidal route. In the postoperative period the ophthalmoplegia gradually disappeared but central hypoadrenia and hypothyroidism occurred. This is the second case in the literature showing that TRH alone and in a low dose may cause pituitary tumor apoplexy. It is concluded that TRH-testing is a risk for the patient with pituitary apoplexy. If, due to the size of the tumor the patients have to be operated on in any case, and the test is not of essential diagnostic value, the TRH-test should be done only in selected cases. Its use in the postoperative evaluation however is without risk for the patients.
报告了一名54岁男性垂体大腺瘤并向鞍上扩展的病例。静脉注射200微克促甲状腺激素释放激素(TRH)进行TRH试验,60分钟后出现严重头痛和呕吐,次日出现眼肌麻痹。CT扫描上的高密度斑显示肿瘤内出血。经蝶窦途径切除了具有宏观和组织学出血迹象的嫌色性腺瘤。术后眼肌麻痹逐渐消失,但出现了中枢性肾上腺功能减退和甲状腺功能减退。这是文献中第二例表明单独使用低剂量TRH可能导致垂体瘤卒中的病例。结论是,TRH试验对垂体卒中患者有风险。如果由于肿瘤大小患者无论如何都必须接受手术,且该试验没有重要的诊断价值,则TRH试验应仅在选定的病例中进行。然而,其在术后评估中的使用对患者没有风险。